Beneficial catalytic immunity to aβ peptide

Rejuvenation Research

Volumn 13, Issue 2-3, 2010, Pages 179-187

  Paul, Sudhir ^a   Planque, Stephanie ^a   Nishiyama, Yasuhiro ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; APOLIPOPROTEIN E4; BAPINEUZUMAB; CATALYTIC ANTIBODY; HYDROLASE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOGLOBULIN M ANTIBODY; LYSINE; SERINE PROTEINASE;

AGING; ALZHEIMER DISEASE; ANTIBODY PRODUCTION; BINDING AFFINITY; BRAIN; CATALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAVY CHAIN; HUMAN; IMMUNE SYSTEM; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOTHERAPY; LIGHT CHAIN; MASS SPECTROMETRY; PHYLOGENY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN HYDROLYSIS; REVIEW;

ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMINO ACID SEQUENCE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, CATALYTIC; HUMANS; IMMUNOTHERAPY; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; TREATMENT OUTCOME;

EID: 77952382873     PISSN: 15491684     EISSN: None     Source Type: Journal    
DOI: 10.1089/rej.2009.0958     Document Type: Review

References (50)

1. Walsh DM, Selkoe DJ. Ab oligomers\a decade of discovery. J Neurochem 2007;101:1172-1184.
2. Lemere CA, Oh J, Stanish HA, Peng Y, Pepivani I, Fagan AM, et al. Cerebral amyloid-b protein accumulation with aging in cotton-top tamarins: A model of early Alzheimer's disease? Rejuvenation Res 2008;11:321-332.
3. Finder VH, Glockshuber R. Amyloid-b aggregation. Neu-rodegener Dis 2007;4:13-27.
4. Ida N, Hartmann T, Pantel J, Schroder J, Zerfass R, Forstl H, et al. Analysis of heterogeneous A4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive Western blot assay. J Biol Chem 1996;271:22908- 22914.
5. Yankner BA, Duffy LK, Kirschner DA. Neurotrophic and neurotoxic effects of amyloid b protein: Reversal by tachy-kinin neuropeptides. Science 1990;250:279-282.
6. Koo EH, Park L, Selkoe DJ. Amyloid b-protein as a substrate interacts with extracellular matrix to promote neurite outgrowth. Proc Natl Acad Sci USA 1993;90:4748-4752.
7. Dahlgren KN, Manelli AM, Stine WB, Jr., Baker LK, Krafft GA, LaDu MJ. Oligomeric and fibrillar species of amyloid-b peptides differentially affect neuronal viability. J Biol Chem 2002,277:32046-32053.
8. Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature 2006;443:768-773.
9. Knobloch M, Farinelli M, Konietzko U, Nitsch RM, Mansuy IM. Ab oligomer-mediated long-term potentiation impairment involves protein phosphatase 1-dependent mechanisms. J Neurosci 2007;27:7648-7653.
10. Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D. Passive immunotherapy against Ab in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation 2004;1:24.
11. Kotilinek LA, Bacskai B, Westerman M, Kawarabayashi T, Younkin L, Hyman BT, et al. Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci 2002;22:6331-6335.
12. Schenk D, Barbour R, Dunn W, Gordon G, Grajeda H, Guido T, et al. Immunization with amyloid-b attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-177.
13. Morgan D, Diamond DM, Gottschall PE, Ugen KE, Dickey C, Hardy J, et al. Ab peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000; 408:982-985.
14. Janus C, Pearson J, McLaurin J, Mathews PM, Jiang Y, Schmidt SD, et al. Ab peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 2000;408:979-982.
15. Gilman S, Koller M, Black RS, Jenkins L, Griffith SG, Fox NC, et al. Clinical effects of Ab immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64: 1553-1562.
16. Vellas B, Black R, Thal LJ, Fox NC, Daniels M, McLennan G, et al. Long-term follow-up of patients immunized with AN1792: Reduced functional decline in antibody respond-ers. Curr Alzheimer Res 2009;6:144-151.
17. Holmes C, Boche D, Wilkinson D, Yadegarfar G, Hopkins V, Bayer A, et al. Long-term effects of Ab42 immunisation in Alzheimer's disease: Follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-223.
18. Lue LF, Walker DG. Modeling Alzheimer's disease immune therapy mechanisms: Interactions of human postmortem microglia with antibody-opsonized amyloid b peptide. J Neurosci Res 2002;70:599-610.
19. Grundman M, Black RS. Clinical trials of bapineuzumab, a b amyloid-targeted immunotherapy in patients with mild moderate Alzheimer's disease. Alzheimers Dement 2008,4: T166; International Conference on Alzheimer's Disease, July 26-31, 2008, Chicago, IL, abstract O3-04-05.
20. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, et al. Increased amyloid b-peptide deposition in cerebral cortex as a consequence of apolipopro-tein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 1993;90:9649-9653.
21. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Ab antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2001;98:8850-8855.
22. Siemers ER, Friedrich S, Dean RA, Sethuraman G, DeMattos R, Jennings D, et al. Safety, tolerability and biomarker effects of an Ab monoclonal antibody administered to patients with Alzheimer's disease. Alzheimers Dement 2008,4:T774. International Conference on Alzheimer's Disease, Chicago, IL, July 26-31, 2008, abstract P4-346.
23. Szabo P, Relkin N, Weksler ME. Natural human antibodies to amyloid b peptide. Autoimmun Rev 2008;7:415-420.
24. Relkin NR, Szabo P, Adamiak B, Burgut T, Monthe C, Lent RW, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-1736.
25. Brody DL, Holtzman DM. Active and passive immuno-therapy for neurodegenerative disorders. Annu Rev Neu-rosci 2008;31:175-193.
26. Wisniewski T, Konietzko U. Amyloid-b immunisation for Alzheimer's disease. Lancet Neurol 2008;7:805-811.
27. Paul S, Nishiyama Y, Planque S, Karle S, Taguchi H, Hanson C, Weksler ME. Antibodies as defensive enzymes. Springer Semin Immunopathol 2005;26:485-503.
28. Paul S, Nishiyama Y, Planque S, Taguchi H. Theory of pro-teolytic antibody occurrence. Immunol Lett 2006;103:8-16.
29. Gao QS, Sun M, Rees AR, Paul S. Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol 1995;253:658-664.
30. Gololobov G, Sun M, Paul S. Innate antibody catalysis. Mol Immunol 1999;36:1215-1222.
31. Sun M, Gao QS, Kirnarskiy L, Rees A, Paul S. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. J Mol Biol 1997;271:374-385.
32. Berberian L, Goodglick L, Kipps TJ, Braun J. Immuno-globulin VH3 gene products: Natural ligands for HIV gp120. Science 1993;261:1588-1591.
33. Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, et al. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J Biol Chem 2004;279:39611-39619.
34. Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, et al. Characterization of gp120 hydrolysis by IgA antibodies from humans without HIV infection. AIDS Res Hum Retroviruses 2007;23:1541-1554.
35. Paul S, Tramontano A, Gololobov G, Zhou YX, Taguchi H, Karle S, et al. Phosphonate ester probes for proteolytic antibodies. J Biol Chem 2001;276:28314-28320.
36. Ekici OD, Paetzel M, Dalbey RE. Unconventional serine proteases: Variations on the catalytic Ser=His=Asp triad configuration. Protein Sci 2008;17:2023-2037.
37. Ramsland PA, Terzyan SS, Cloud G, Bourne CR, Farrugia W, Tribbick G, et al. Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural pro-teolytic antibody. Biochem J 2006;395:473-481.
38. Hifumi E, Ohara K, Niimi Y, Uda T. Removal of catalytic activity by EDTA from antibody light chain. Biometals 2000; 13:289-294.
39. Hifumi E, Morihara F, Hatiuchi K, Okuda T, Nishizono A, Uda T. Catalytic features and eradication ability of antibody light chain UA15-L against H. pylori. J Biol Chem 2008;283: 899-907.
40. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem 2003;278: 20429-20435.
41. Paul S, Sun M, Mody R, Tewary HK, Stemmer P, Massey RJ, et al. Peptidolytic monoclonal antibody elicited by a neuro-peptide. J Biol Chem 1992;267:13142-13145.
42. Wirsching P, Ashley JA, Lo CH, Janda KD, Lerner RA. Reactive immunization. Science 1995;270:1775-1782.
43. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 1989;244:1158-1162.
44. Rangan SK, Liu R, Brune D, Planque S, Paul S, Sierks MR. Degradation of b-amyloid by proteolytic antibody light chains. Biochemistry 2003;42:14328-14334.
45. Taguchi H, Planque S, Nishiyama Y, Symersky J, Boivin S, Szabo P, et al. Autoantibody-catalyzed hydrolysis of amyloid b peptide. J Biol Chem 2008;283:4714-4722.
46. Elovaara I, Icen A, Palo J, Erkinjuntti T. CSF in Alzheimer's disease. Studies on blood-brain barrier function and intra-thecal protein synthesis. J Neurol Sci 1985;70:73-80.
47. Taguchi H, Planque S, Sapparapu G, Boivin S, Hara M, Nishiyama Y, Paul S. Exceptional amyloid b peptide hydrolyzing activity of nonphysiological immunoglobulin variable domain scaffolds. J Biol Chem 2008;283:36724-36733.
48. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS. Neprilysin: An enzyme candidate to slow the progression of Alzheimer's disease. Am J Pathol 2008;172:1342-1354.
49. Dooley H, Flajnik MF. Antibody repertoire development in cartilaginous fish. Dev Comp Immunol 2006;30:43-56.
50. Planque S, Bangale Y, Song XT, Karle S, Taguchi H, Poin-dexter B, et al. Ontogeny of proteolytic immunity: IgM ser-ine proteases. J Biol Chem 2004;279:14024-14032.